Ketogenic Dietary Therapy for Infantile Spasms

Written by:  Elizabeth Neal MSC PhD RD
Matthew’s Friends Medical Advisory Board
Ketogenic Research Dietitian at
UCL – Great Ormond Street Institute of Child Health Updated Aug 2025: Dr Archana Desurkar
Matthew’s Friends Medical Advisory Board
Consultant Paediatric Neurologist at Sheffield Children’s Hospital

Infantile spasms (IS), first reported in 1841, and newly classified as Infantile Epileptic Spasm Syndrome (1), typically presents within the first year of life as spasm-type seizures. It is often associated with an EEG abnormality known as hypsarrhythmia and developmental regression; this triad of symptoms being termed West Syndrome (2). Standard treatment consists if ICISS protocol which uses oral steroids and vigabatrin, though some centres may use ACTH. These treatments will successfully control seizures in majority of cases though relapses are common but have significant side effects that limit their duration of use (3). Second line treatments medications such as benzodiazepines, or ketogenic dietary therapy (KDT), with alternative anti- seizure medications (ASMs) also used if first-line treatments are unsuccessful, however with variable success (4). Continued intractable seizures in an infant will impact on long-term cognitive and behavioural outcomes, require frequent clinical reviews with considerable cost implications for health services due to need for regular clinical reviews, hospital treatment, medications, and support of other therapies. Alternative treatment options for this syndrome should therefore be explored as early as possible.

KDT is a high fat, restricted carbohydrate dietary regime that has been used since the 1920s and includes the traditional Classical and Medium Chain Triglyceride diets and less restrictive Modified Atkins diet (MAD) and Low Glycaemic Index Treatment. Efficacy of these diets in epilepsy has been demonstrated in many studies including randomised controlled trials in children (5, 6, 7, 8). Reviews support KDT as a safe, tolerable, and effective treatment in infants with medication-resistant epilepsy (9, 10, 11) and a recent randomised open label trial of 136 infants reported Classical KDT to be similar in efficacy and tolerability to a further ASM and safe to use in infants with epilepsy (12). Retrospective studies looking specifically at infants with IS have also shown KDT to be effective and well-tolerated (13, 14, 15, 16).

One study reporting significant spasm improvements and less side effects when KDT was used as an alternative first-line therapy to ACTH (17). One study of 119 infants who had genetic sequencing prior to KDT reported a higher response rate to diet in those with CDKL5 mutation (18).

Many prospective and retrospective studies identify consistent efficacy with KDT in ISS, even those with refractoriness to first lien therapy.

A large prospective study also demonstrate KDT efficacy in IS unresponsive to first line treatments. In a study of 104 infants, 64% had over 50% improvement in spasms after 6 months on KD, 29 of whom became seizure free (19). Three smaller studies have also reported positive results (20, 21, 22) although another study of 22 children has questioned whether complete seizure response to KDT can be achieved in highly refractive IS

(23). A larger prospective controlled study of KDT efficacy in 227 infants divided outcomes into three grades depending on extent of spasm reduction and hypsarrhythmia remission; for all grades, efficacy in diet group was superior to that in control group (ASM adjustment only) (24).

A trial comparing efficacy and tolerability of KDT with standard high-dose ACTH treatment for IS followed 101 infants (32 in a randomised trial and 69 in a parallel cohort) including those with and without prior vigabatrin treatment: results showed similar electroclinical remission in ACTH and diet groups after 28 days but better tolerance in the KDT group. The authors concluded that without prior vigabatrin treatment, ACTH should be first choice to achieve short-term seizure remission, however with prior vigabatrin, KDT was as effective as ACTH with lower long-term relapse rate (25).

A systematic review of KDT efficacy in IS included 13 observational studies with results supporting benefit of the diet: of a total 341 patients, a median of 65% experienced over 50% spasm reduction and 35% were spasm-free, although this fell to 10% with longer follow up data (26), even in head to head trial comparing KDT vs ACTH

International consensus recommendations suggest that KDT should be strongly considered early in the course of epilepsy management in children with certain specific conditions, including IS (27). UK guidelines on management of epilepsy also suggest KDT should be considered under the guidance of a tertiary epilepsy specialist in certain childhood-onset epilepsy syndromes including IS (nice.org.uk:ng217). Early KDT use in infants is recommended: a review of outcomes in 115 children with a range of epilepsy syndromes, over half with IS, found significantly more infants under 18 months of age achieved seizure freedom when compared to those over 18 months, this difference was even greater when infants under 9 months of age were examined separately (16).

Practical guidelines for KDT use in infants recommend a Classical ketogenic diet (28), although MAD has also been shown to be successful in this group (29, 30, 31). Breastfeeding or expressed human milk can be included within a KDT prescription without compromising diet effectiveness (32, 33, 34), and with careful screening, KDT used safely in a neonatal intensive care setting (35). It is recommended that young infants typically under 9 months of age are admitted to initiate KDT as they are at a higher risk of hypoglycaemia or other initial AE.

Common early adverse effects of KDT in infants are hypoglycaemia and vomiting (36, 37), with other side effects including gastro-intestinal disturbances especially constipation and reflux, altered lipid levels, renal stones, and acidosis; most complications being transient and controlled with diet adjustment and monitoring

(28). Although there have been concerns about the effect of KDT on linear growth in infants, this has not been shown to be a problem after either 3 or 12 months on diet (38, 39); initiating a lower ketogenic ratio dietary protocol may also reduce risk (40).

We therefore propose that infants with IS who have failed appropriate first-line treatment options are funded for an initial assessment of suitability for KDT. Evaluation after two or three months on diet is suggested to allow adequate assessment of benefit and appropriate fine-tuning of the dietary prescription to individual needs; earlier assessment after one month may be needed in infants on KDT as first, second- or third-line treatment in view of the risks of uncontrolled seizures (28). Although it is often suggested that children with epilepsy who are benefiting from KDT continue this for at least two years, duration of treatment could be shorter in patients with IS who become seizure-free; one study reported no adverse effect on seizure outcomes and less risk of growth disturbances when diet treatment was tapered down after 8 months (41). in seizure free patients.

References

  1. Zuberi SM, Wirrell E, Yozawitz E et al (2022) ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Epilepsia 63(6):1349–97.
  2. Hollenshead PP, Jackson CN, Cross JV, et al (2023) Treatment modalities for infantile spasms: current considerations and evolving strategies in clinical Neurol Sci. doi: 10.1007/s10072-023-07078-z.
  3. Hancock EC, Osborne JP, Edwards SW (2013) Treatment of infantile Cochrane Database Syst Rev. (6):CD001770.
  4. Velíšek L, Velíšková, J (2020) Modeling epileptic spasms during infancy: Are we heading for the treatment yet? Pharmacol 212:107578.
  5. Neal EG, Chaffe HM, Schwartz R, et al (2008) The ketogenic diet in the treatment of epilepsy: a randomised controlled Lancet Neurol. 7:500-6.
  6. Lambrechts DA, de Kinderen RJ, Vles JS, et al (2017) A randomized controlled trial of the ketogenic diet in refractory childhood Acta Neurol Scand. 135(2):231-9.
  7. Sharma S, Sankhyan N, Gulati S, Agarwala A (2013) Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled Epilepsia 54(3):481-6.
  8. Lakshminarayanan K, Agarawal A, Panda PK, et al (2021) Efficacy of low glycemic index diet therapy (LGIT) in children aged 2-8 years with drug-resistant epilepsy: A randomized controlled Epilepsy Res.171:106574.
  9. Lyons L, Schoeler NE, Langan D, Cross JH (2020) Use of ketogenic diet therapy in infants with epilepsy: A systematic review and meta-analysis. Epilepsia 61(6):1261-81.
  10. Falsaperla R, D’Angelo G, Praticò AD, et al (2020) Ketogenic diet for infants with epilepsy: A literature Epilepsy Behav. 112:107361.
  11. Dressler A, Trimmel-Schwahofer P (2020) The ketogenic diet for infants: How long can you go? Epilepsy 164:106339.
  12. Schoeler N, Marston L, Lyons L, et al (2023) Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial Lancet 22: 1113–24.
  13. Kossoff EH, Pyzik PL, McGrogan JR, et al (2002) Efficacy of the ketogenic diet for infantile Pediatrics 109(5):780-3.
  14. Rubenstein JE, Kossoff EH, Pyzik PL, et al (2005) Experience in the use of the ketogenic diet as early J Child Neurol. 20(1):31- 4.
  15. Eun SH, Kang HC, Kim DW, Kim HD (2006) Ketogenic diet for treatment of infantile Brain Dev. 28(9):566-71.
  16. Dressler A, Trimmel-Schwahofer P, Reithofer E, et al (2015) The ketogenic diet in infants–Advantages of early Epilepsy Res. 116:53-8.
  17. Kossoff EH, Hedderick EF, Turner Z, Freeman JM (2008) A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 49(9):1504-9.
  18. Wang J, Zhang J, Yang Y, et al (2022). Efficacy of Ketogenic Diet for Infantile Spasms in Chinese Patients With or Without Monogenic Front Pediatr. 10:842666.

1G. Hong AM, Turner Z, Hamdy RF, Kossoff EH (2010) Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia 51(8):1403-7.

  1. Pires ME, Ilea A, Bourel E, et al (2013) Ketogenic diet for infantile spasms refractory to first-line treatments: an open prospective Epilepsy Res. 105(1-2):189-94.
  2. Kayyali HR, Gustafson M, Myers T, et al (2014) Ketogenic diet efficacy in the treatment of intractable epileptic Pediatr Neurol. 50(3):224-7.
  3. Hanifiha M, Shervin Badv R, Mahmoudi M, Tavasoli AR (2022) The Efficacy of the Ketogenic Diet in Improving Seizures and EEG Findings in Patients with Refractory Infantile Iran J Child Neurol. 16(4):45-54.
  4. Hussain SA, Shin JH, Shih EJ, et al (2016) Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic Seizure. 35:59-64.
  5. Zhang J, Chen G, Wang J, et al (2021) Efficacy of the ketogenic diet on ACTH- or corticosteroid-resistant infantile spasm: a multicentre prospective control Epileptic Disord. 23(2):337-45.
  6. Dressler A, Benninger F, Trimmel-Schwahofer P, et al (2019) Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled Epilepsia 60(3):441- 51.
  7. Prezioso G, Carlone G, Zaccara G, Verrotti A (2018) Efficacy of ketogenic diet for infantile spasms: A systematic review. Acta Neurol 137(1):4-11.
  8. Kossoff EH, Zupec-Kania BA, Auvin S, et al (2018) Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Epilepsia Open. 3(2):175-92.
  9. Van der Louw E, van den Hurk D, Neal E, et al (2016) Ketogenic diet guidelines for infants with refractory Eur J Paediatr Neurol. 20(6):798-809.

2G. Sharma S, Dabla S, Kaushik JS (2023) Modified Atkins Diet vs. Ketogenic Diet in the Management of Children with Epileptic Spasms Refractory to First Line Treatment: An Open Labelled, Randomized Controlled Trial. Indian J Pediatr. 90(10):969-73.

  1. Sharma S, Goel S, Kapoor D, et al (2021) Evaluation of the Modified Atkins Diet for the Treatment of Epileptic Spasms Refractory to Hormonal Therapy: A Randomized Controlled J Child Neurol. 36(8):686-91.
  2. Dou X, Jia S, Wang Z, et al (2023) A case-control evaluation of Spasm control and Tolerability of the Modified Atkins diet versus classic ketogenic diet in Chinese Children with infantile epileptic spasms Seizure 110:238-43.
  3. Le Pichon JB, Thompson L, Gustafson M, Abdelmoity A (2019) Initiating the ketogenic diet in infants with treatment refractory epilepsy while maintaining a breast milk Seizure 69:41-3.
  4. Dressler A, Häfele C, GiordanoV, et al (2020) The Ketogenic Diet Including Breast Milk for Treatment of Infants with Severe Childhood Epilepsy: Feasibility, Safety, and Breastfeed Med 5(2):72-8.
  5. van der Louw E, Trimmel-Schwahofer P, Devlin A, et al (2024) Human milk and breastfeeding during ketogenic diet therapy in infants with epilepsy: Clinical practice Dev Med Child Neurol. doi: 10.1111/dmcn.15928. Epub ahead of print.
  6. Thompson L, Fecske E, Salim M, Hall A (2017) Use of the ketogenic diet in the neonatal intensive care unit-Safety and tolerability. Epilepsia 58(2):e36-9.
  7. Armeno M, Verini A, Caballero E, Cresta A, Valenzuela GR, Caraballo R (2021) Long-term effectiveness and adverse effects of ketogenic diet therapy in infants with drug-resistant epilepsy treated at a single center in Epilepsy Res. 178:106793.
  8. Ruiz-Herrero J, Cañedo-Villarroya E, Pérez-Sebastián I, Bernardino-Cuesta B, Pedrón-Giner C (2021) Efficacy and safety of ketogenic dietary therapies in A single-center experience in 42 infants less than two years of age. Seizure. 92:106-11.
  9. Numis AL, Yellen MB, Chu-Shore CJ, et al (2011) The relationship of ketosis and growth to the efficacy of the ketogenic diet in infantile Epilepsy Res. 96(1-2):172-5.
  10. Liu Y, Wan J, Gao Z, Xu L, Kong L (2021) Ketogenic diet and growth in Chinese infants with refractory epilepsy. Asia Pac J Clin Nutr. 30(1):113-21.
  11. Hsieh TY, Su TY, Hung KY, et al (2023) Feasibility of ketogenic diet therapy variants for refractory epilepsy in neonates to infants under 2 years Epilepsy Behav. 146:109315.
  12. Kang HC, Lee YJ, Lee JS, et al (2011) Comparison of short- versus long-term ketogenic diet for intractable infantile Epilepsia 52(4):781-7.

> Download a PDF Version of This

© Matthews Friends 2025